Pre-clinical and early clinical stage

Biological mechanisms
Normalising disease-disrupted protein homeostasis:
- Clearance of toxic proteins
- Regulation of transcription and translation of targets

Target class
Targeting RNA and/or proteins genetically and causally linked to disease

Indications: Rare neurological disorders and sub-populations of neurodegenerative disease
- Hereditary forms of Parkinson Disease
- Rare neurological disorders including:
  - Multiple System Atrophy
  - Familial Amyotrophic Lateral Sclerosis
  - Spinocerebellar Ataxia
  - Progressive Supranuclear Palsy
  - Genetically driven paediatric epilepsias

Modalities and drug delivery
- Small molecules
- Oligonucleotides, ASO
- Technologies to improve the efficacy/specificity of cellular and brain delivery and distribution (ASO)
- Systemic administration for CNS RNA technologies

Partnering Interests

Global BD

Jerund Sollid, PhD
Global Lead, Neuroscience & Immuno-Inflammation BD
Mobile: +33 765 76 66 59 / jorund.sollid@servier.com

David Théron, PharmD
Business Development Project Director
Mobile: +33 6 49 55 11 98
david.theron@servier.com

R&D External Innovation

Chloé Leprêtre
Head Global Search & Evaluation, R&D External Innovation
Mobile: +33 6 08 23 49 29
chloe.lepretre@servier.com

Tian Li, PhD
Associate Director, Search & Evaluation, Asia-Pacific
Mobile: +86 13811628153
tian.li@servier.com

Local BD

USA

Pat Fetaya, MBA, MSc
Head, US Business Development, Servier Pharmaceuticals
Mobile: +1.609.285.8275
pat.fetaya@servier.com

Asia

Cynthia Wang, MBA, MSc
Director, Global Business Development Asia-Pacific,
Mobile: +86 13910100149
cynthia.wang@servier.com

Global BD Coordination

Bénédicte Barrault
GBD Coordination Officer, Neuroscience & Immuno-Inflammation
benedicte.barrault@servier.com

Active Partnerships
**A partner of choice**

A partner with strong commitment

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier long-term vision applies to its partnership philosophy.

A partner with a global presence

With €4.98bn of revenue in 2022 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

A partner with proven expertise and experience

Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.

A partner you can rely on

Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets.

---

**Partnering interests**

<table>
<thead>
<tr>
<th>Oncology</th>
<th>Immuno-oncology</th>
<th>Neurology</th>
<th>Cardiovascular &amp; Metabolism diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discovery &amp; Early Clinical Focus</strong></td>
<td><strong>Cancer cell Targeting</strong></td>
<td><strong>Hereditary forms of Parkinson Disease</strong></td>
<td>Acquire or license market-ready or</td>
</tr>
<tr>
<td></td>
<td>• Synthetic lethality</td>
<td>• Small molecules</td>
<td>mature assets for some geographies</td>
</tr>
<tr>
<td></td>
<td>• Apoptosis</td>
<td>• Antibodies, Bispecifics, ADCs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Precision oncology</td>
<td>• T cell targeting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Epigenetic regulators</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Modalities</strong></td>
<td><strong>Modalities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immuno-inflammation</strong></td>
<td><strong>Immuno-inflammation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Autoantibody-driven autoimmune diseases</td>
<td>• Small molecules</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• And other diseases sharing similar</td>
<td>• Antibodies, Bispecifics, ADCs, Fusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pathophysiological mechanisms</td>
<td>proteins</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Oligonucleotides, ASO</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Hereditary forms of Parkinson Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Rare neurological disorders including:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Multiple System Atrophy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Familial Amyotrophic Lateral Sclerosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Spinocerebellar Ataxia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Progressive Supranuclear Palsy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Genetically driven paediatric</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>epilepsy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Partnership is embedded in our culture with highly engaged and diverse teams partnering for a shared purpose - contributing to therapeutic progress to serve patient needs. Our partnership approach serves one goal: to bring life-changing treatments to patients faster. We strive to always put patients first, leading to better outcomes for ourselves and our partners.